Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20689682 | 0.75 | ALDH1A1 (0.48) | — | |
| SCHEMBL20689137 | 0.72 | ALDH1A1 (0.51) | — | |
| SCHEMBL30452501 | 0.71 | TYK2 (0.47) | TYK2 | |
| SCHEMBL23753623 | 0.71 | NOS3 (0.39) | TYK2 | |
| SCHEMBL20689567 | 0.71 | TYK2 (0.47) | TYK2 | |
| SCHEMBL25069900 | 0.71 | CHRNB2 (0.40) | — | |
| SCHEMBL31572570 | 0.69 | TYK2 (0.32) | TYK2 | |
| SCHEMBL16794710 | 0.69 | OGA (0.36) | OGATYK2 | |
| SCHEMBL16812435 | 0.68 | ALDH1A1 (0.44) | TYK2 | |
| SCHEMBL16794650 | 0.68 | OPRM1 (0.38) | TYK2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056447-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | OGA 3386/4885TYK2 1/4885CNR2 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.